Author’s response to reviews

Title: Dalbavancin Treatment in a Deep Sternal Wound MRSA Infection after Coronary Artery Bypass Surgery: A Case Report

Authors:

Aneta Guzek (aguzek@wim.mil.pl)
Grzegorz Suwalski (gsuwalski@wim.mil.pl)
Dariusz Tomaszewski (dtomaszewski@wim.mil.pl)
Zbigniew Rybicki (zrybicki@wim.mil.pl)

Version: 1 Date: 11 Dec 2017

Author’s response to reviews:

First of all, the authors would like to thank the reviewer for his or her time and valuable suggestions. The reviewer pointed out the following recommendations:

(1) Add the dates of surgery to figure 1. Also, I’m not sure what the top line of that figure represents.

The day of the surgery was marked in the figure; the top line represents the days of the hospitalization. We have changed and rearranged the figure to improve its clarity.

(2) It’s worth noting that vancomycin use did result in a reduction in CRP values over time. The authors clearly state that there was a concern that clinical improvement was insufficient but there was a residual collection that probably required surgical drainage, and cultures done at the debridement were presumably all negative.

We have added information about the reduction of CRP values after vancomycin administration to the text.

(2) MIC value of dalbavancin should be added to Table 1.

We have added the MIC value of dalbavancin to the table.

(3) Three references should be added to the paper (Dunne et al., 2015; Jandourek, Shevchenko et al., 2017; Dunne et al., 2016).

We have added the three references to the manuscript.
(4) Consider adding a statement to the conclusion that this case report supports a definitive clinical trial in dalbavancin for the treatment of osteomyelitis.

We have added such a statement to the conclusion.